JP2017511316A5 - - Google Patents

Download PDF

Info

Publication number
JP2017511316A5
JP2017511316A5 JP2016559626A JP2016559626A JP2017511316A5 JP 2017511316 A5 JP2017511316 A5 JP 2017511316A5 JP 2016559626 A JP2016559626 A JP 2016559626A JP 2016559626 A JP2016559626 A JP 2016559626A JP 2017511316 A5 JP2017511316 A5 JP 2017511316A5
Authority
JP
Japan
Prior art keywords
antibody
composition
composition according
medicament
psoriasis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016559626A
Other languages
English (en)
Japanese (ja)
Other versions
JP6596014B2 (ja
JP2017511316A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/021613 external-priority patent/WO2015153144A1/en
Publication of JP2017511316A publication Critical patent/JP2017511316A/ja
Publication of JP2017511316A5 publication Critical patent/JP2017511316A5/ja
Application granted granted Critical
Publication of JP6596014B2 publication Critical patent/JP6596014B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016559626A 2014-03-31 2015-03-19 爪および頭皮乾癬の治療方法 Active JP6596014B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461972638P 2014-03-31 2014-03-31
US61/972,638 2014-03-31
US201462031850P 2014-07-31 2014-07-31
US62/031,850 2014-07-31
US201462041879P 2014-08-26 2014-08-26
US62/041,879 2014-08-26
PCT/US2015/021613 WO2015153144A1 (en) 2014-03-31 2015-03-19 Methods of treating nail and scalp psoriasis

Publications (3)

Publication Number Publication Date
JP2017511316A JP2017511316A (ja) 2017-04-20
JP2017511316A5 true JP2017511316A5 (https=) 2019-05-09
JP6596014B2 JP6596014B2 (ja) 2019-10-23

Family

ID=52808190

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016559626A Active JP6596014B2 (ja) 2014-03-31 2015-03-19 爪および頭皮乾癬の治療方法

Country Status (11)

Country Link
US (1) US20170174772A1 (https=)
EP (1) EP3126392B1 (https=)
JP (1) JP6596014B2 (https=)
KR (2) KR20160130248A (https=)
CN (1) CN106456751B (https=)
AU (1) AU2015241373B2 (https=)
CA (1) CA2944605C (https=)
ES (1) ES2760002T3 (https=)
MY (1) MY184189A (https=)
SG (1) SG11201607881SA (https=)
WO (1) WO2015153144A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
HRP20171939T1 (hr) 2010-01-15 2018-03-23 Kirin-Amgen, Inc. Formulacija protutijela i režimi terapije
CN105534996B (zh) * 2016-02-24 2018-05-01 长沙佰顺生物科技有限公司 一种治疗银屑病的药物组合物
GB201612043D0 (en) * 2016-07-11 2016-08-24 Crescendo Biologics Ltd Composition for treatment of disorders
JP7033774B2 (ja) * 2017-08-25 2022-03-11 国立大学法人 東京大学 抗サイトカイン抗体療法
US10960006B2 (en) * 2018-01-31 2021-03-30 Twi Pharmaceuticals, Inc. Topical formulations comprising tofacitinib
US12161748B2 (en) 2018-01-31 2024-12-10 Twi Biotechnology, Inc. Topical formulations comprising tofacitinib
WO2019163945A1 (ja) 2018-02-22 2019-08-29 学校法人東海大学 Ｉｌ－１７ａ活性阻害剤およびその用途
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
WO2021048359A1 (en) * 2019-09-11 2021-03-18 Bausch Health Ireland Limited Methods of treating nonalcoholic fatty liver disease (nafld) using il-17ra antibody
KR20220070244A (ko) * 2019-09-25 2022-05-30 도꾜 다이가꾸 전신성 강피증 치료용 의약 조성물

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
GB8807803D0 (en) 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
ATE289350T1 (de) 1989-04-21 2005-03-15 Amgen Inc Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas
DE3922089A1 (de) 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
ES2072330T5 (es) 1989-05-18 2013-06-24 Yeda Research And Development Co., Ltd. Proteínas de unión II al Factor de Necrosis Tumoral, su purificación y anticuerpos frente a los mismos
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
AU630497B2 (en) 1989-09-05 1992-10-29 Immunex Corporation Tumor necrosis factor-alpha and -beta receptors
ATE194384T1 (de) 1989-09-12 2000-07-15 Hoffmann La Roche Tnf-bindende proteine
JPH03127800A (ja) 1989-10-13 1991-05-30 Teijin Ltd 腫瘍壊死因子活性抑制物質
CA2032191C (en) 1989-12-13 1999-05-18 David Wallach Expression of the recombinant tumor necrosis factor binding protein i (tbp-i)
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
GB2246569A (en) 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
ES2120949T4 (es) 1990-06-28 2011-12-29 Sanofi-Aventis Deutschland Gmbh 50% Proteinas de fusión con porciones de inmunoglobulinas, su preparación y empleo.
WO1992001002A1 (en) 1990-07-11 1992-01-23 Teijin Limited Tumor necrosis factor activity inhibitor and production thereof
ATE190629T1 (de) 1991-01-18 2000-04-15 Amgen Inc Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten
DK0575545T3 (da) 1991-03-15 2003-09-15 Amgen Inc Pegylering af polypeptider
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
WO1993007863A1 (en) 1991-10-15 1993-04-29 Mullarkey Michael F Methods and compositions for treating allergic reactions
NZ251820A (en) 1992-03-30 1996-07-26 Immunex Corp Fusion proteins with tnf-r (tumour necrosis factor-receptor) peptide linked to another tnf-r or an il-1r (interleukin-1-receptor) peptide
JPH07509223A (ja) 1992-04-30 1995-10-12 アムジェン インコーポレイテッド インターロイキン−１媒介疾患および腫瘍壊死因子媒介疾患の治療方法
JPH05312248A (ja) 1992-05-08 1993-11-22 Nissan Motor Co Ltd シフトレバー装置
KR100232688B1 (ko) 1992-09-15 1999-12-01 스코트 쥐. 홀퀴스트 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
NZ306653A (en) 1995-03-23 1999-03-29 Immunex Corp Isolated dna il-17 receptors
US7030565B2 (en) 2004-07-27 2006-04-18 Jerrell Penn Hollaway Lamp control circuit with selectable color signals
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
UA99716C2 (ru) * 2006-10-02 2012-09-25 Кирин-Амген Инк. Антитело, которое специфично связывает человеческий il-17 рецептор а (il-17ra)
HRP20171939T1 (hr) * 2010-01-15 2018-03-23 Kirin-Amgen, Inc. Formulacija protutijela i režimi terapije
PH12013500660B1 (en) * 2010-10-08 2017-10-27 Novartis Ag Methods of treating psoriasis using il-17 antagonists
US9413463B2 (en) 2013-08-30 2016-08-09 Google Inc. Apparatus and method for efficient two-way optical communication where transmitter may interfere with receiver
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Similar Documents

Publication Publication Date Title
JP2017511316A5 (https=)
CA2944605C (en) Methods of treating nail and scalp psoriasis
JP6554155B2 (ja) Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法
JP2025172841A (ja) Ｉｌ－４ｒアンタゴニストを投与することによるアトピー性皮膚炎の治療方法
US20230303677A1 (en) Methods of treating new-onset plaque type psoriasis using il-17 antagonists
KR20200088857A (ko) Il-17 길항제에 의한 화농성 한선염의 치료
JP2018515493A5 (https=)
CA3225933A1 (en) Il-13 antibodies for the treatment of atopic dermatitis
Vinicki et al. Sustained remission after long-term biological therapy in patients with large vessel vasculitis: an analysis of ten cases
US20250042985A1 (en) Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp)
CN114423455A (zh) 用于治疗系统性硬化症的药物组合物
EP4267184B1 (en) Interleukin 5 binding protein dosage regimen
JPWO2021195530A5 (https=)
US20220403018A1 (en) Methods of treating lichen planus using interleukin (il-17) antagonists
WO2026078117A1 (en) Anti-il-5 antibody in the treatment of chronic rhinosinusitis with nasal polyps
CN121889429A (zh) 用于治疗嗜酸性肉芽肿性多血管炎的IL-5R-α抗体
JP2025537966A (ja) 潰瘍性大腸炎を治療する方法
IL316022A (en) Method of treating mild to moderate psoriasis with il-23 specific antibody
JPWO2021191220A5 (https=)
Bubna Secukinumab: Introduction
JPWO2022136209A5 (https=)